Yes, looking at the latest CMRX presentation (13/4/21) it seems like ONC201 is something that they want to hold on to.
https://ir.chimerix.com/events-and-presentations
"ONC201 provides attractive near-term opportunity
• Unprecedented single agent activity in recurrent H3 K27M-mutant glioma
• Clear path to registration, pivotal data anticipated in 2021
• Attractive commercial market potential
- >$500M global peak sales opportunity in first indication
- Extraordinary awareness of ONC201 among KOLs
- Mutation already identified through standard diagnostics
• Compelling single agent response in second indication
• Attractive safety, easy administration
• Strong IP portfolio into mid to late 2030s
• Path ahead leverages organizational strengths"
Yes, looking at the latest CMRX presentation (13/4/21) it seems...
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)